Florian Stehling

ORCID: 0000-0002-2417-2048

Also affiliated with Zentrum für Kinderheilkunde, University of Duisburg-Essen

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial”.

Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial

The Lancet Respiratory Medicine(2025)10.1016/s2213-2600(24)00407-7

N/A

1.4DataRank · unranked

50 citations

Ajay S. Kasi, Jessica E. Pittman, Renée Jensen, L. Thia, Philip Robinson +44 more

Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study

American Journal of Respiratory and Critical Care Medicine(2022)10.1164/rccm.202202-0392oc

N/A

0DataRank · unranked

141 citations

Rossa Brugha, Silvia Gärtner, Julian Legg, Alexander Mœller, Pedro Mondéjar-López +19 more